临床报道

西罗莫司治疗儿童弥漫性肺淋巴管瘤病1例报告

  • 叶泽慧 ,
  • 姜小丽
展开
  • 重庆医科大学附属儿童医院呼吸科 国家儿童健康与疾病临床医学研究中心 儿童发育疾病研究教育部重点实验室 儿童代谢与炎症性疾病重庆市重点实验室(重庆 400014
姜小丽 电子信箱: jiangxiao2009521@126.com

收稿日期: 2024-04-28

  录用日期: 2025-01-09

  网络出版日期: 2025-08-27

A case report of sirolimus in the treatment of diffuse pulmonary lymphangiomatosis in children

  • YE Zehui ,
  • JIANG Xiaoli
Expand
  • Department of Respiratory, Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Chongqing 400014, China

Received date: 2024-04-28

  Accepted date: 2025-01-09

  Online published: 2025-08-27

摘要

目的 探讨儿童弥漫性肺淋巴管瘤病的临床特征与诊疗策略,以提高早期诊断与治疗水平,改善患儿预后。方法 回顾性分析我院呼吸科收治的1例弥漫性肺淋巴管瘤病患儿的临床资料,总结其临床特点、诊疗过程,并结合相关文献,探讨该病的综合治疗方案及预后。结果 该患儿接受西罗莫司口服治疗3年,临床症状显著缓解,胸部影像学检查提示明显改善。结论 西罗莫司治疗儿童弥漫性肺淋巴管瘤病疗效确切,不良反应少,有助于改善患儿远期预后。

本文引用格式

叶泽慧 , 姜小丽 . 西罗莫司治疗儿童弥漫性肺淋巴管瘤病1例报告[J]. 临床儿科杂志, 2025 , 43(9) : 705 -709 . DOI: 10.12372/jcp.2025.24e0399

Abstract

Objective To explore the clinical characteristics and treatment strategies of diffuse pulmonary lymphangiomatosis in children, in order to improve the early diagnosis and treatment level and the prognosis of children. Methods The clinical data of a child with diffuse pulmonary lymphangiomatosis admitted to the respiratory department of our hospital were retrospectively analyzed. The clinical manifestations, diagnostic process, and treatment outcomes were systematically summarized. Furthermore, current comprehensive treatment options and prognostic factors were discussed in light of relevant literature. Results The child received sirolimus treatment for 3 years, and the clinical symptoms were significantly relieved. Chest CT showed significant improvement. Conclusion Sirolimus demonstrates promising therapeutic efficacy in the management of diffuse pulmonary lymphangiomatosis in children, with a favorable safety profile and the potential to significantly enhance long-term prognosis.

参考文献

[1] 沈秋英, 农光民, 顾永耀. 儿童弥漫性肺淋巴管瘤病二例[J]. 中华儿科杂志, 2016, 54(10): 781-782.
  Shen QY, Nong GM, Gu YY. Two cases of diffuse pulmonary lymphangioma in children[J]. Zhonghua Erke Zazhi, 2016, 54(10): 781-782.
[2] Ernotte C, Médart L, Collignon L. Diffuse pulmonary lymphangiomatosis[J]. J Belg Soc Radiol, 2018, 102(1): 64.
[3] Gurskyt? V, Zeleckien? I, Maskoliūnait? V, et al. Successful treatment of diffuse pulmonary lymphangiomatosis with sirolimus[J]. Respir Med Case Rep, 2020, 29: 101014.
[4] Triana P, Dore M, Cerezo VN, et al. Sirolimus in the treatment of vascular anomalies[J]. Eur J Pediatr Surg, 2017, 27(1): 86-90.
[5] Luisi F, Torre O, Harari S. Thoracic involvement in generalised lymphatic anomaly (or lymphangiomatosis)[J]. Eur Respir Rev, 2016, 25(140): 170-177.
[6] Zheng G, Tang H, Su R, et al. A gene missense mutation in diffuse pulmonary lymphangi- omatosis with thrombocytopenia: a case report[J]. Medicine (Baltimore), 2020, 99(39): e21941.
[7] Faul JL, Berry GJ, Colby TV, et al. Thoracic lymphangiomas, lymphangiectasis, lymphangiomatosis, and lymphatic dysplasia syndrome[J]. Am J Respir Crit Care Med, 2000, 161(3Pt 1): 1037-1046.
[8] Moreno RP, Hernández Y, Garrido P, et al. Diffuse pulmonary lymphangiomatosis with pleural and pericardial involvement. Pediatric case report[J]. Arch Argent Pediatr, 2021, 119(3): e264-e268.
[9] Liu JR, Shen WB, Wen Z, et al. Clinical analysis of two cases with diffuse pulmonary lymphatic disease[J]. Zhonghua Erke Zazhi, 2016, 54(5): 360-364.
[10] Ricci KW, Iacobas I. How we approach the diagnosis and management of complex lymphatic anomalies[J]. Pediatr Blood Cancer, 2022, 69(Suppl 3): e28985.
[11] 曾祥妮, 吴爱民, 李岚, 等. 一例弥漫性肺淋巴管瘤病支气管镜下表现及分析[J]. 临床儿科杂志, 2024, 42(12): 1047-1050..
  Zeng XN, Wu AM, Li L, et al. A case report of a rare case of diffuse pulmonary lymphangiomatosis with bronchoscopic presentation[J]. Linchuang Erke Zazhi, 2024, 42(12): 1047-1050.
[12] Sun X, Shen W, Xia S, et al. Diffuse pulmonary lymphangiomatosis: MDCT findings after direct lymphangiography[J]. AJR Am J Roentgenol, 2017, 208(2): 300-305.
[13] 潘登, 丛金鹏, 王芳芳, 等. 弥漫性肺淋巴管瘤病二例报[J]. 临床医学进展, 2020, 10(7): 1397-1404.
  Pan D, Cong JP, Wang FF, et al. Diffuse pulmonary lymphangiomatosis: report of two cases[J]. Linchuang Yixue Jinzhan, 2020, 10(7): 1397-1404.
[14] Biscotto I, Rodrigues RS, Forny DN, et al. Diffuse pulmonary lymphangiomatosis[J]. J Bras Pneumol, 2019, 45(5): e20180412.
[15] Lim HJ, Han J, Kim HK, et al. A rare case of diffuse pulmonary lymphangiomatosis in a middle-aged woman[J]. Korean J Radiol, 2014, 15(2): 295-299.
[16] Ozeki M, Nozawa A, Yasue S, et al. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies[J]. Orphanet J Rare Dis, 2019, 14(1): 141.
[17] Ricci KW, Hammill AM, Mobberley-Schuman P, et al. Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease[J]. Pediatr Blood Cancer, 2019, 66(5): e27614.
[18] Rodriguez-Laguna L, Agra N, Iba?ez K, et al. Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly[J]. J Exp Med, 2019, 216(2): 407-418.
[19] Reinglas J, Ramphal R, Bromwich M. The successful management of diffuse lymphangio matosis using sirolimus: a case report[J]. Laryngoscope, 2011, 121(9): 1851-1854.
[20] Sun X, Lu C, Huang Z, et al. Diagnosis and treatment of diffuse pulmonary lymphangioma in children: a case report[J]. Exp Ther Med, 2023, 25(4): 175.
[21] Dimiene I, Bieksiene K, Zaveckiene J, et al. Effective initial treatment of diffuse pulmonary lymphangiomatosis with sirolimus and propranolol: a case report[J]. Medicina (Kaunas), 2021, 57(12): 1308.
[22] Amodeo I, Colnaghi M, Raffaeli G, et al. The use of sirolimus in the treatment of giant cystic lymphangioma: four case reports and update of medical therapy[J]. Medicine (Baltimore), 2017, 96(51): e8871.
[23] Ferrara N. Vascular endothelial growth factor: basic science and clinical progress[J]. Endocr Rev, 2004, 25(4): 581-611.
[24] Onyeforo E, Barnett A, Zagami D, et al. Diffuse pulmonary lymphangiomatosis treated with bevacizumab[J]. Respirol Case Rep, 2018, 7(1): e00384.
文章导航

/